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Abstract
Adipose-derived	mesenchymal	stem	cell	(ADSC)-based	regenerative	therapies	have	
shown	potential	for	use	in	many	chronic	diseases.	Aging	diminishes	stem	cell	regener-
ative	potential,	yet	it	is	unknown	whether	stem	cells	from	aged	donors	cause	adverse	
effects	 in	 recipients.	ADSCs	can	be	obtained	using	minimally	 invasive	approaches	
and	possess	low	immunogenicity.	Nevertheless,	we	found	that	transplanting	ADSCs	
from	old	donors,	but	not	those	from	young	donors,	induces	physical	dysfunction	in	
older	recipient	mice.	Using	single-cell	transcriptomic	analysis,	we	identified	a	natu-
rally	occurring	senescent	cell-like	population	in	ADSCs	primarily	from	old	donors	that	
resembles	 in	vitro-generated	senescent	cells	with	regard	to	a	number	of	key	path-
ways.	Our	 study	 reveals	 a	 previously	 unrecognized	 health	 concern	 due	 to	ADSCs	
from old donors and lays the foundation for a new avenue of research to devise 
interventions	to	reduce	harmful	effects	of	ADSCs	from	old	donors.
K E Y W O R D S
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Adipose-derived	 mesenchymal	 stem	 cells	 (ADSCs)	 or	 “preadipo-
cytes” have been increasingly suggested for use in regenerative 
medicine as a treatment for a wide range of diseases due to their 
multipotency	and	accessibility.	Older	adults	represent	most	likely	re-
cipients	of	ADSC	therapies	given	the	high	burden	of	diseases	in	this	
population.	Since	autologous	ADSCs	are	preferred	in	the	clinic,	it	is	
essential	to	understand	age-related	changes	influencing	these	cells.	
Emerging	evidence	suggests	that	ADSCs	from	aged	donors	have	re-
duced	regenerative	potential,	leading	to	diminished	therapeutic	ef-
ficacy	(Khong	et	al.,	2019;	Liu	et	al.,	2017;	Ye	et	al.,	2016).	However,	
it	is	unknown	whether	transplanting	ADSCs	from	aged	donors	might	
cause unexpected or even harmful effects in recipients. This is espe-
cially	important	for	older	adults,	since	they	tend	to	be	more	vulnera-
ble and less resilient to such stresses.
To	examine	this,	we	isolated	ADSCs	from	12	young	(6–7	months,	
referred	to	as	young	ADSCs)	and	12	old	(28–31	months,	referred	to	
as	old	ADSCs)	C57BL/6	male	mice.	We	transplanted	1	x	106	ADSCs	
from young or old donors i.p.	into	syngeneic	20-month-old	C57BL/6	
male	mice	 (Figure	1a).	Four	 to	 six	weeks	after	 transplantation,	we	
tested	maximal	walking	speed	(RotaRod),	grip	strength,	physical	en-
durance	(hanging	test,	treadmill),	daily	activity,	food	intake,	and	body	
weight	change	to	assess	overall	physical	function	in	recipients,	based	
on	criteria	used	in	clinical	practice	(Fried	et	al.,	2001).	ADSCs	from	old	
donors	 significantly	 impaired	walking	 speed,	 grip	 strength,	 endur-
ance,	and	daily	activity	of	older	recipient	mice	after	transplantation,	
compared	with	mice	transplanted	with	the	same	number	of	ADSCs	
from	young	donors	 (Figure	1b-e).	No	statistically	significant	differ-
ences	were	observed	in	terms	of	treadmill,	body	weight	change,	food	
intake,	or	remaining	lifespan	(Figure	S1a-d),	which	might	be	due	to	an	
insufficient	number	of	transplanted	old	ADSCs	to	cause	detectible	
changes	in	these	tests.	Overall,	these	findings	suggest	that	ADSCs	
from	old	donors	can	 induce	physical	 frailty,	which	 is	highly	associ-
ated	with	morbidity	and	loss	of	independence(Ensrud	et	al.,	2009).	
Thus,	 regenerative	 approaches	entailing	 transplantation	of	ADSCs	
from	aged	donors	might	generate	previously	unrecognized	risks.
In	a	previous	study,	we	demonstrated	that	transplanting	a	small	
number	of	in	vitro-generated	senescent	ADSCs	(stable	proliferative	
arrest	 caused	 by	 various	 stresses	 (Campisi	 &	 d'Adda	 di	 Fagagna,	
2007)	induces	physical	dysfunction	in	mice	(Xu	et	al.,	2018).	To	de-
fine	 a	 potential	 naturally	 occurring	 senescent	 cell-like	 population,	
we	conducted	single-cell	transcriptome	(SCT)	analysis.	We	obtained	
high-quality	 single-cell	 transcriptomes	 (5,565	 genes	 and	 33,811	
polyadenylated	RNA	transcripts	detected	per	cell	on	average)	from	
3,604	and	1,876	ADSCs	 from	young	and	old	donors,	 respectively.	
Cdkn1a (p21)	and	Cdkn2a	(p16)	are	two	markers	frequently	associ-
ated	with	cellular	senescence	(Campisi	&	d'Adda	di	Fagagna,	2007),	
both of which were highly expressed in cells isolated from the old 
donors	(Figure	2a).	We	manually	set	a	cutoff	of	p21	expression	level,	
which is a higher expression level than in 97% of cells from young 
donors.	We	 considered	 cells	 to	 be	p21high if their p21 levels were 
higher	than	this	cutoff.	We	found	that	8.9%	of	cells	from	old	donors	
were p21high	compared	with	3%	of	cells	in	young	donors	(Figure	2a),	
both of which are similar to the percentages of senescent cells 
observed	in	ADSCs	isolated	from	young	and	old	human	donors	(Xu	
et	al.,	2015).	We	used	p21 rather than p16 because the difference of 
p21 levels between young and old cells was more significant than p16 
(Figure	2a,c)	and	p16 level positively correlates with p21 in p21high 
cells (p	<	.001).	In	addition,	we	found	that	cells	from	old	donors	pro-
liferated	at	a	slower	rate	and	contained	more	SA-βgal+ and p21high 
cells	compared	with	the	cells	from	young	donors	(Figure	S2),	which	is	
consistent with an increased abundance of senescent cells among the 
cells	isolated	from	the	old	donors.	Notably,	we	documented	the	tran-
scriptomic signatures of naturally occurring p21high	 senescent-like	
cells for the first time. By comparing all the distinctly expressed 
genes	within	this	population	using	Ingenuity	Pathway	Analysis	(IPA),	
we	observed	altered	upstream	regulators	and	pathways	(Figure	2b)	
in these naturally occurring p21high cells that are similar to those of 
in	 vitro-generated	 “artificial”	 senescent	 cells,	 including	 Senescent	
Cell	 Anti-Apoptotic	 Pathways	 (SCAPs;	 increased	 cell	 survival	 and	
decreased	apoptosis)	 (Zhu	et	al.,	2015),	NF-κB	(Chien	et	al.,	2011),	
IL6/JAK	(Xu	et	al.,	2015),	mTOR	(Herranz	et	al.,	2015;	Laberge	et	al.,	
2015),	FOXO	(Baar	et	al.,	2017),	and	HMGB1	(Davalos	et	al.,	2013)	
pathways. These findings suggest that p21high cells might contribute 
to the physical dysfunction and validate the physiological relevance 
of	the	in	vitro-generated	senescent	cells	that	have	been	extensively	
used to study the biology of senescence and for drug screening. To 
gain	more	 insight	 into	 deleterious	 effects	 of	 aging	on	 the	ADSCs,	
we	 compared	 transcriptomes	 of	 ADSCs	 isolated	 from	 young	 ver-
sus	old	donors	using	edgeR	(Robinson,	McCarthy,	&	Smyth,	2010).	 
Among	15,565	detected	 genes,	 3,787	were	up-regulated	 and	948	
were	down-regulated	(–log10P	value	>	4)	in	the	cells	from	old	donors	
(Figure	2c	and	Supporting	dataset).	Several	senescence-associated	
secretory	 phenotype	 (SASP)-related	 genes	 were	 up-regulated	 in	
cells	 from	old	donors	 (Figure	2c).	 For	 validation,	we	measured	 se-
creted protein levels of these genes in conditioned media from young 
versus	old	ADSCs	by	multiplex	protein	analysis	(Xu	et	al.,	2015)	.	In	
most	cases,	the	mRNA	differences	were	consistent	with	differences	
in	secreted	proteins	 (Figure	2d).	Using	 IPA,	we	detected	a	number	
of	pathways	that	were	distinctly	expressed	in	ADSCs	isolated	from	
young	 versus	 old	 donors	 (Figure	 2e),	 affording	 an	 opportunity	 to	
develop	 interventions	 that	could	 reverse	aged	ADSCs	 into	a	more	
“youthful”	state,	potentially	reducing	harmful	effects	and	improving	
regenerative	efficacy.	One	 limitation	of	our	 study	 is	 that	we	used	
allogenic transplantation (although the donors and the recipients 
were	syngeneic),	which	might	not	fully	represent	autologous	trans-
plantation	used	 in	clinic.	 In	 future	studies,	more	 focused,	 in-depth	
mechanistic	insights	into	how	ADSCs	from	old	donors	exert	their	ad-
verse	effects	need	to	be	obtained.	Potential	mechanisms	include	cel-
lular	senescence,	inflammaging,	and	resulting	sarcopenia.	Also,	SCT	
analysis	using	other	senescence-related	markers	such	as	p16,	Il6,	and	
Cxcl1 would be helpful for understanding the biology of senescence.
In	summary,	we	demonstrate	that	old	ADSCs	can	impair	physical	
function	in	older	recipients,	indicating	a	potential	health	concern	re-
garding	transplanting	aged	ADSCs.	By	SCT,	we	identified	a	naturally	
occurring p21high	 senescent-like	cell	population.	Currently,	 there	 is	
limited knowledge about in vivo senescent cells due to the difficulty 
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in isolating them because of their low numbers and lack of ideal mark-
ers.	 To	our	 knowledge,	we	obtained	 the	 transcriptomic	 signatures	
of in vivo p21high	senescent-like	cells	for	the	first	time,	which	could	
assist in understanding the biology of senescence and drug develop-
ment.	In	addition,	we	uncovered	many	signaling	pathways	that	vary	
between	ADSCs	isolated	from	young	versus	old	donors.	Our	study	
potentially begins new avenues of research to discover whether 
pharmacological	interventions,	such	as	senolytic	drugs	(Tchkonia	&	
Kirkland,	2018)	or	anti-inflammatory	drugs,	can	prevent	or	reverse	
dysfunction	caused	by	transplanting	ADSCs	or	even	organs	from	old	
donors	(Lau,	Kennedy,	Kirkland,	&	Tullius,	2019)	and	improve	clinical	
outcomes of transplantation for older patients.
F I G U R E  1  Adipose-derived	mesenchymal	stem	cell	(ADSCs)	from	old	donors	impair	physical	function.	(a)	Experimental	design.	(b-e)	
Quantification	of	maximal	walking	speed	(relative	to	baseline)	(b),	grip	strength	(c),	hanging	endurance	(d),	daily	activity	(e)	of	21-month-old	
male	C57BL/6	mice	4–6	weeks	after	being	injected	with	1	×	106	ADSCs	from	old	or	young	donors	or	no	(sham)	ADSCs.	For	b,	c,	d,	n = 10 for 
sham,	n	=	9	for	Young,	n	=	9	for	old.	For	e,	n = 8 for all groups. Results are mean ± SEM.	*,	p	<	.05;	Student's	t test
F I G U R E  2  Single-cell	transcriptome	analysis.	(a)	Violin	plots	for	p21 and p16	expression	levels	in	young	and	old	cell	populations.	(b)	IPA	
analysis of p21high	cells.	Positive	Z-score	indicates	up-regulation	in	p21high	cells.	(c)	Volcano	plot	of	differentially	expressed	genes	between	
cells	from	young	and	old	donors.	The	top	20	most	significantly	altered	genes,	and	several	selected	genes	are	highlighted.	–log10	P	value	and	
log2(fold	change)	values	are	shown.	(d)	Secreted	cytokine	levels	in	conditioned	media	from	ADSCs	isolated	from	young	and	old	donors.	n = 4. 
Results are mean ± SEM.	*,	p	<	.05;	Student's	t	test.	(e)	IPA	analysis	of	canonical	pathways	enriched	in	adipose-derived	mesenchymal	stem	
cell	(ADSCs)	from	old	versus	young	donors
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